Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The rVSV-ZEBOV Ebolavirus vaccine confers protection within days after immunization, suggesting the contribution of innate immune responses. We report modulation of rVSV-ZEBOV vaccinee blood CD56<sup>+</sup> NK cell numbers, NKG2D or NKp30 surface receptor expression, Killer Immunoglobulin-like Receptor (KIR)<sup>+</sup> cell percentages and NK-cell-related genes on day 1 post immunization. Inverse correlations existed between the concentration of several plasma cytokines and inhibitory KIR<sup>+</sup> CD56<sup>dim</sup> or cytokine-responsive CD56<sup>bright</sup> NK cells. Thus, NK cells may contribute to the early protective efficacy of rVSV-ZEBOV in humans.

Original publication

DOI

10.1038/s41541-020-0179-4

Type

Journal

NPJ vaccines

Publication Date

01/2020

Volume

5

Addresses

1Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Keywords

VEBCON Consortium, VSV-EBOVAC Consortium, VSV-EBOPLUS Consortium